Clinical Trials Logo

Stargardt Macular Dystrophy clinical trials

View clinical trials related to Stargardt Macular Dystrophy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02402660 Recruiting - Stargardt Disease Clinical Trials

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

TEASE
Start date: August 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD